Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The post RNA-based immunotherapy eradicates melanoma tumours appeared first on Drug Discovery World (DDW).

RNA 52

RNA Bioassay Genome Genomics 52

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.

Bioassay 130

Bioassay Development RNA Drugs 130

Drug Discovery World

MAY 10, 2023

Carcinogenicity testing For decades, the two-year rodent bioassay has been the regulatory standard used to determine the carcinogenic potential of new drugs. This process historically involved lifetime carcinogenicity bioassays in two species. Figure 1: Comparing Carcinogenicity Testing Timelines in Transgenic vs. Standard Mice.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

Drug Discovery World

NOVEMBER 30, 2023

Promega had two posters from which to share insight, which included: ‘Cell-based luminescent reporter bioassays for immunotherapies targeting macrophage effector functions’, and ‘Development of bioluminescent no-wash Fc gamma receptor binding immunoassay to guide the development of antibody therapeutics’.

Antibody 57

Antibody Protein Engineer In-Vivo 57